A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC)
Karin Purshouse(Western General Hospital), Jeremy Crew, Caroline Haddon, Leena Elhussein(University of Oxford), Victoria K. Woodcock(Churchill Hospital), Vincenzo Cerundolo(John Radcliffe Hospital), Mark R. Middleton(University of Oxford), Andrew Protheroe(University of Oxford), Sarah P. Blagden(Churchill Hospital), Gillian Verrall, J-L. Kwok, Chrissie Butcher(University of Oxford), Monica Salio
Cited by 1
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
|Nature Medicine|2002|1.6k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k
Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines
|European Journal of Cancer|2019|589